On August 17, INNOVENT BIO rose 3.78% in regular trading, trading at 97.4 HKD/share, with turnover of HKD 219 million.

The rally was driven by a combination of catalysts: the company recently partnered with Meituan to explore an instant retail model for pharmaceutical products and launched small-specification new products, expanding its commercialization channels. Additionally, the company announced that its board will convene on August 25 to review interim results, heightening market anticipation for the upcoming mid-year report.

The optimism is underpinned by previously disclosed strong financials — first-half product revenue exceeded RMB 8.2 billion, representing over 55% year-over-year growth, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY, significantly beating market expectations. Multiple investment banks have reiterated buy ratings, with Goldman Sachs raising its target price to HKD 111.68, BOCOM International setting a target of HKD 118, and Citi reaffirming its target at HKD 115, all citing accelerating commercialization momentum and growing confidence in the company's RMB 20 billion domestic revenue target for next year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)